COMMUNIQUÉS West-GlobeNewswire

GATC Health Announces Launch of Derisq: The Definitive AI Report for Predictive Risk Assessment of Drug Candidates at Fierce Biotech Week 2025
07/10/2025
Derisq delivers actionable insights about drug safety, efficacy and off-target risks prior to committing development capital BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging [...]
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
07/10/2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc [...]
Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR
07/10/2025
Strengthens Balance Sheet with Over $60 Million in Cash 1 , Excluding Bitcoin Treasury David Beckham Co-Founded IM8 on Track to Achieve $100 Million ARR in First Year, Becoming One of the Fastest-Growing Supplement [...]
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
07/10/2025
FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for [...]
Clover Health to Report Third Quarter 2025 Financial Results on November 4, 2025
07/10/2025
WILMINGTON, Del., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great [...]
Profusa Invests Additional $1 Million in Digital Treasury Assets
07/10/2025
BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
07/10/2025
$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in [...]
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
07/10/2025
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025
Torino, Italy, October 7 – Resalis Therapeutics , a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense [...]
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025
Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN, Italy, October 07, [...]
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
07/10/2025
The two new patents expand protection for Salipro Biotech's proprietary technology for stabilizing and extracting challenging membrane proteins, crucial for developing therapeutics against high-value drug targets like [...]
Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
07/10/2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, [...]
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT
07/10/2025
NEW YORK, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025
Former GSK and Sanofi executive, led Cervarix ® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalist Strengthens Bioxodes leadership following encouraging Phase 2a [...]
Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC
07/10/2025
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix ® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années d’expérience en [...]
Allegro showcases superior shock-absorbing capacity of injectable hydrogel for osteoarthritis at CellMech
07/10/2025
Comparative testing against four market-leading hydrogels demonstrates Hydrocelin’s superior shock absorbing capacity Significantly improves the shock-absorbing capacity of pathological equine synovial fluid in [...]
Carlsbad Dental Care Expands Access to Modern Dentistry with New Patient Special and Financing Options
07/10/2025
Carlsbad, CA, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Carlsbad Dental Care, a trusted local practice led by Dr. Raymond Ngo, is improving access to high-quality dental care for families across the Carlsbad community with its [...]
Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
07/10/2025
Single dose of avigbagene parvec (FLT201) demonstrates sustained clinical benefit and favorable safety up to two years after withdrawal of prior chronic therapy Data underscore potential to set new standard-of-care [...]

Pages